Abstract
The TNF family members RANKL and its receptor RANK have initially been described as factors expressed on T cells and dendritic cells (DCs), respectively, and have been shown to augment the ability of DCs to stimulate naive T cell proliferation and enhance DC survival. Since another, yet soluble receptor for RANKL, namely OPG, was initially characterized as a factor inhibiting osteoclast development and bone resorption, it was somewhat enigmatic at first why one and the same genes would be essential both for the immune system and bone development – two processes that on first sight do not have much in common. However, in a series of experiments it was conclusively shown that RANKL-expressing T cells can also activate RANK-expressing osteoclasts, and thereby in principal mimicking RANKL-expressing osteoblasts. These findings lead to a paradigm shift and helped to coin the term osteoimmunology in order to account for the crosstalk of immune cells and bone. More importantly was that these findings also provided a rationale for the bone loss observed in patients with a chronically activated immune system such as in rheumatoid arthritis, leukemias, or the like, arguing that T cells, which were activated during the course of the disease to fight it off, also express RANKL, which induces osteoclastogenesis and thereby shifts the intricate balance of bone deposition and resorption in favor of the latter. Through knockout mice it became also clear that the RANKL-RANK-OPG system is involved in other processes such as in controlling autoimmunity or immune responses in the skin. We will briefly summarize the role of RANK(L) signaling in the immune system before we discuss some of the recent data we and others have obtained on the role of RANK(L) in controlling autoimmunity and immune responses in the skin.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- TNF:
-
Tumor Necrosis Factor
- RANKL:
-
Receptor Activator of Nuclear Factor-κB (NF-κB) Ligand
- RANK:
-
Receptor Activator of Nuclear Factor-κB (NF-κB)
- OPG:
-
Osteoprotegerin
- DCs:
-
Dendritic Cells
- LT:
-
Lymphotoxin
- PPs:
-
Peyer’s Patches
- LNs:
-
Lymph Nodes
- ALPS:
-
Autoimmune Lymphoproliferative Syndrome
- cTEC:
-
Cortical Thymic Epithelial Cell
- mTEC:
-
Medullary Thymic Epithelial Cell
- TRA:
-
Tissue Restricted Antigen
- AIRE:
-
Autoimmune Regulator
- LTi:
-
Lymphoid Tissue Inducer
- Tregs:
-
eRgulatory T Cells
- LCs:
-
Langerhans Cells
- RA:
-
Rheumatoid Arthritis
- BMD:
-
Bone Mineral Density
References
Abu-Amer, Y. (2001). IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. J Clin Invest, 107: 1375–1385.
Akiyama, T., Shimo, Y., Yanai, H. et al. (2008). The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity, 29: 423–437.
Alimzhanov, M.B., Kuprash, D.V., Kosco-Vilbois, M.H. et al. (1997). Abnormal development of secondary lymphoid tissues in lymphotoxin beta-deficient mice. Proc Natl Acad Sci U S A, 94: 9302–9307.
Anderson, G., Lane, P.J., & Jenkinson, E.J. (2007). Generating intrathymic microenvironments to establish T-cell tolerance. Nat Rev Immunol, 7: 954–963.
Anderson, D.M., Maraskovsky, E., Billingsley, W.L. et al. (1997). A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature, 390: 175–179.
Anderson, M.S., Venanzi, E.S., Klein, L. et al. (2002). Projection of an immunological self shadow within the thymus by the aire protein. Science, 298: 1395–1401.
Bachmann, M.F., Wong, B.R., Josien, R. et al. (1999). TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med, 189: 1025–1031.
Banchereau, J., & Steinman, R.M. (1998). Dendritic cells and the control of immunity. Nature, 392: 245–252.
Bendele, A., McComb, J., Gould, T. et al. (1999). Animal models of arthritis: relevance to human disease. Toxicol Pathol, 27: 134–142.
Bendixen, A.C., Shevde, N.K., Dienger, K.M. et al. (2001). IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor gamma 1. Proc Natl Acad Sci USA, 98: 2443–2448; Akiyama, T., Maeda, S., Yamane, S. et al. (2005). Dependence of self-tolerance on TRAF6-directed development of thymic stroma. Science, 308: 248–251.
Boehm, T., Scheu, S., Pfeffer, K. et al. (2003). Thymic medullary epithelial cell differentiation, thymocyte emigration, and the control of autoimmunity require lympho-epithelial cross talk via LTbetaR. J Exp Med, 198: 757–769.
Body, J.J., Facon, T., Coleman, R.E. et al. (2006). A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res, 12: 1221–1228.
Bone, H.G., Bolognese, M.A., Yuen, C.K. et al. (2008). Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab, 93: 2149–2157.
Brandt, J., Haibel, H., Cornely, D. et al. (2000). Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum, 43: 1346–1352.
Campagnuolo, G., Bolon, B., & Feige, U. (2002). Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum, 46: 1926–1936; Bolon, B., Campagnuolo, G., & Feige, U. (2002). Duration of bone protection by a single osteoprotegerin injection in rats with adjuvant-induced arthritis. Cell Mol Life Sci, 59: 1569–1576.
Chin, R.K., Lo, J.C., Kim, O. et al. (2003). Lymphotoxin pathway directs thymic Aire expression. Nat Immunol, 4: 1121–1127.
Cohen, S.B., Dore, R.K., Lane, N.E. et al. (2008). Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum, 58: 1299–1309.
De Togni, P., Goellner, J., Ruddle, N.H. et al. (1994). Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science, 264: 703–707.
Dong, C. (2006). Diversification of T-helper-cell lineages: finding the family root of IL-17-producing cells. Nat Rev Immunol, 6: 329–333.
Dougall, W.C., & Chaisson, M. (2006). The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev, 25: 541–549.
Dougall, W.C., Glaccum, M., Charrier, K. et al. (1999). RANK is essential for osteoclast and lymph node development. Genes Dev, 13: 2412–2424.
Ebeling, P.R., Erbas, B., Hopper, J.L. et al. (1998). Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids. J Bone Miner Res, 13: 1283–1289.
Emery, J.G., McDonnell, P., Burke, M.B. et al. (1998). Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem, 273: 14363–14367.
Fata, J.E., Kong, Y.Y., Li, J. et al. (2000). The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell, 103: 41–50.
Feldmann, M., Brennan, F.M., & Maini, R.N. (1996). Rheumatoid arthritis. Cell, 85: 307–310.
Feldmann, M., Brennan, F.M., & Maini, R.N. (1996). Role of cytokines in rheumatoid arthritis. Annu Rev Immunol, 14: 397–440.
Futterer, A., Mink, K., Luz, A. et al. (1998). The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity, 9: 59–70.
Fu, Y.X., Chaplin, D.D. (1999). Development and maturation of secondary lymphoid tissues. Annu Rev Immunol, 17: 399–433.
Green, E.A., Choi, Y., & Flavell, R.A. (2002). Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity, 16: 183–191.
Green, E.A., & Flavell, R.A. (2000). The temporal importance of TNFalpha expression in the development of diabetes. Immunity, 12: 459–469.
Harrington, L.E., Hatton, R.D., Mangan, P.R. et al. (2005). Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol, 6: 1123–1132.
Hikosaka, Y., Nitta, T., Ohigashi, I. et al. (2008). The cytokine RANKL produced by positively selected thymocytes fosters medullary thymic epithelial cells that express autoimmune regulator. Immunity, 29: 438–450.
Hofbauer, L.C., Khosla, S., Dunstan, C.R. et al. (1999). Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology, 140: 4367–4370.
Horwood, N.J., Elliott, J., Martin, T.J. et al. (2001). IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J Immunol, 166: 4915–4921.
Hsu, H., Lacey, D.L., Dunstan, C.R. et al. (1999). Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A, 96: 3540–3545.
Ingulli, E., Mondino, A., Khoruts, A. et al. (1997). In vivo detection of dendritic cell antigen presentation to CD4(+) T cells. J Exp Med, 185: 2133–2141
Irla, M., Hugues, S., Gill, J. et al. (2008). Autoantigen-specific interactions with CD4+ thymocytes control mature medullary thymic epithelial cell cellularity. Immunity, 29: 451–463.
Josien, R., Li, H.L., Ingulli, E. et al. (2000). TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med, 191: 495–502.
Josien, R., Wong, B.R., Li, H.L. et al. (1999). TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol, 162: 2562–2568.
Kanematsu, M., Sato, T., Takai, H., et al. (2000). Prostaglandin E2 induces expression of receptor activator of nuclear factor-kappa B ligand/osteoprotegrin ligand on pre-B cells: implications for accelerated osteoclastogenesis in estrogen deficiency. J Bone Miner Res, 15: 1321–1329.
Keffer, J., Probert, L., Cazlaris, H. et al (1991). Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. Embo J, 10: 4025–4031,
Kim, D., Mebius, R.E., MacMicking, J.D. et al. (2000). Regulation of peripheral lymph node genesis by the tumor necrosis factor family member TRANCE. J Exp Med, 192: 1467–1478.
Kong, Y.Y., Feige, U., Sarosi, I. et al. (1999). Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature, 42: 304–309.
Kong, Y.Y., Yoshida, H., Sarosi, I. et al. (1999). OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397: 315–323.
Koni, P.A., Sacca, R., Lawton, P. et al. (1997). Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity, 6: 491–500.
Korganow, A.S., Ji, H., Mangialaio, S. et al. (1999). From systemic T cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity, 10: 451–461.
Kotake, S., Udagawa, N., Hakoda, M. et al. (2001). Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum, 44: 1003–1012.
Kotake, S., Udagawa, N., Takahashi, N. et al. (1999). IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest, 103: 1345–1352.
Kouskoff, V., Korganow, A.S., Duchatelle, V., &et al. (1996). Organ-specific disease provoked by systemic autoimmunity. Cell, 87: 811–822.
Kyewski, B., & Klein, L. (2006). A central role for central tolerance. Annu Rev Immunol, 24: 571–606.
Lacey, D.L., Timms, E., Tan, H.L. et al. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93: 165–176.
Li, J., Sarosi, I., Yan, X.Q. et al. (2000). RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A, 97: 1566–1571.
Lipton, A. (2006). Future treatment of bone metastases. Clin Cancer Res, 12: 6305s–6308s.
Lipton, A., Steger, G.G., Figueroa, J. et al. (2007). Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol, 25: 4431–4437.
Loser, K., Mehling, A., Loeser, S. et al. (2006). Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells. Nat Med, 12: 1372–1379.
Mahamed, D.A., Marleau, A., Alnaeeli, M. et al. (2005). G(-) anaerobes-reactive CD4+ T-cells trigger RANKL-mediated enhanced alveolar bone loss in diabetic NOD mice. Diabetes, 54: 1477–1486.
Manoury-Schwartz, B., Chiocchia, G., Bessis, N. et al. (1997). High susceptibility to collagen-induced arthritis in mice lacking IFN-gamma receptors. J Immunol, 158: 5501–5506.
Matsumoto, M., Mariathasan, S., Nahm, M.H. et al. (1996). Role of lymphotoxin and the type I TNF receptor in the formation of germinal centers. Science, 271: 1289–1291.
Mebius, R.E. (2003). Organogenesis of lymphoid tissues. Nat Rev Immunol, 3: 292–303.
Mebius, R.E., Rennert, P., & Weissman, I.L. (1997). Developing lymph nodes collect CD4+CD3- LTbeta+ cells that can differentiate to APC, NK cells, and follicular cells but not T or B cells. Immunity, 7: 493–504.
Mehling, A., Loser, K., Varga, G. et al. (2001). Overexpression of CD40 ligand in murine epidermis results in chronic skin inflammation and systemic autoimmunity. J Exp Med, 194: 615–628.
McClung, M.R., Lewiecki, E.M., Cohen, S.B. et al. (2006). Denosumab in postmenopausal women with low bone mineral density. N Engl J Med, 354: 821–831.
Mori, H., Kitazawa, R., Mizuki, S. et al. (2002). RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. Histochem Cell Biol, 117: 283–292.
Muller-Ladner, U., Gay, R.E., & Gay, S. (1998). Molecular biology of cartilage and bone destruction. Curr Opin Rheumatol, 10: 212–219.
Nakashima, T., Wada, T., & Penninger, J.M. (2003). RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol, 15: 280–287.
Oliveri, M.B., Mautalen, C.A., Rodriguez Fuchs, C.A. et al. (1991). Vertebral compression fractures at the onset of acute lymphoblastic leukemia in a child. Henry Ford Hosp Med J, 39: 45–48.
Oxenius, A., Campbell, K.A., Maliszewski, C.R. et al. (1996). CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions. J Exp Med, 183: 2209–2218.
Oliveri, MB., Mautalen, C.A., Rodriguez Fuchs, C.A. et al. (1991). Vertebral compression fractures at the onset of acute lymphoblastic leukemia in a child. Henry Ford Hosp Med J, 39: 45–48.
Oxenius, A., Campbell, K.A., Maliszewski, C.R. et al. (1996). CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions. J Exp Med, 183: 2209–2218.
Panayi, G.S., Lanchbury, J.S., & Kingsley, G.H. (1992). The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum, 35: 729–735.
Park, H., Li, Z., Yang, X.O. et al. (2005). A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol, 6: 1133–1141.
Pettit, A.R., Ji, H., von Stechow, D. et al. (2001). TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol, 159: 1689–1699.
Piepkorn, B., Kann, P., Forst, T. et al. (1997). Bone mineral density and bone metabolism in diabetes mellitus. Horm Metab Res, 29: 584–591.
Quezada, S.A., Jarvinen, L.Z., Lind, E.F. et al. (2004). CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol, 22: 307–328.
Redlich, K., Hayer, S., Maier, A. et al. (2002). Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. Arthritis Rheum, 46: 785–792.
Rennert, P.D., Browning, J.L., & Hochman, P.S. (1997). Selective disruption of lymphotoxin ligands reveals a novel set of mucosal lymph nodes and unique effects on lymph node cellular organization. Int Immunol, 9: 1627–1639.
Rennert, P.D., James, D., Mackay, F. et al. (1998). Lymph node genesis is induced by signaling through the lymphotoxin beta receptor. Immunity, 9: 71–79.
Romas, E., Sims, N.A., Hards, D.K. et al. (2002). Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol, 161: 1419–1427.
Rossi, S.W., Jenkinson, W.E., Anderson, G. et al. (2006). Clonal analysis reveals a common progenitor for thymic cortical and medullary epithelium. Nature, 441: 988–991.
Rossi, S.W., Kim, M.Y., Leibbrandt, A. et al. (2007). RANK signals from CD4(+)3(-) inducer cells regulate development of Aire-expressing epithelial cells in the thymic medulla. J Exp Med, 204: 1267–1272.
Roy, M., Waldschmidt, T., Aruffo, A. et al. (1993). The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol, 151: 2497–2510.
Sakaguchi, S. (2005). Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol, 6: 345–352.
Sato, K., Suematsu, A., Okamoto, K. et al. (2006). Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med, 203: 2673–2682.
Seitz, M., & Hunstein, W. (1985). Enhanced prostanoid release from monocytes of patients with rheumatoid arthritis and active systemic lupus erythematosus. Ann Rheum Dis, 44: 438–445.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this paper
Cite this paper
Leibbrandt, A., Penninger, J.M. (2009). Novel Functions of RANK(L) Signaling in the Immune System. In: Choi, Y. (eds) Osteoimmunology. Advances in Experimental Medicine and Biology, vol 658. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-1050-9_9
Download citation
DOI: https://doi.org/10.1007/978-1-4419-1050-9_9
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-1049-3
Online ISBN: 978-1-4419-1050-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)